Clinical Trial News and Research

RSS

OrthoAccel Technologies completes the sale of AcceleDent System in the UK

OrthoAccel Technologies, Inc., developers of the AcceleDent System, which is an acceleration device for orthodontics, has just completed the sale of the product to several key opinion leaders in the United Kingdom.

30 Oct 2009

NIH launches randomized trail to determine whether lower BP goal cuts the risk of heart and kidney diseases

The National Institutes of Health is launching a large multicenter randomized clinical trial to determine whether maintaining blood pressure levels lower than current recommendations further reduces the risk of cardiovascular and kidney diseases, or age-related cognitive decline.

30 Oct 2009

Vitamin D deficiency may account for increased risk of end-stage renal disease in African Americans

Low levels of vitamin D may account for nearly 60 percent of the elevated risk of end-stage renal disease (ESRD) in African Americans, according to a report in the December Journal of the American Society of Nephrology (JASN).

30 Oct 2009

USC to develop stem cell-based treatment for age-related macular degeneration with CIRM grant

Physician-researchers at the University of Southern California (USC) received a nearly $16 million grant from the California Institute of Regenerative Medicine (CIRM) to fund the development of a stem cell-based treatment for age-related macular degeneration, the leading cause of vision loss and blindness among the elderly.

29 Oct 2009

CIRM awards Cedars-Sinai Heart Institute $5.5 million grant for development of cardiac stem cell therapies

A team of Cedars-Sinai Heart Institute stem cell researchers led by Eduardo Marb-n, M.D., Ph.D. has been awarded a four-year, $5.5 million grant from the California Institute of Regenerative Medicine (CIRM) to fund research leading to clinical trials of new treatments for heart attack patients.

29 Oct 2009

Bolton Medical reports first U.S. trial of its Relay Plus System for endovascular stent-graft procedures

Bolton Medical announced today the first use of its new Relay Plus System in the U.S. Relay Clinical Trial. The case took place at the University of Pennsylvania Medical Center in Philadelphia, PA.

29 Oct 2009

Phase Forward’s InForm GTM electronic data capture solution to be implemented by Bausch & Lomb

Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, today announced a multi-year contract with renowned eye health company Bausch & Lomb. The agreement calls for Bausch & Lomb to implement Phase Forward’s InForm™ Global Trial Management (GTM) electronic data capture (EDC) solution, including the Central Coding™ module, in all of its trials, including Surgical, Vision Care and Pharmaceuticals products.

29 Oct 2009

World’s first Cesium-131 lung implants performed

IsoRay, Inc. announced today that starting on August 12, 2009, Dr. Bhupesh Parashar from the Department of Radiation Oncology, and Dr. Nasser Altorki of the Department of Cardiothoracic Surgery at Weill Cornell Medical Center performed the world’s first Cesium-131 lung implants.

29 Oct 2009

Third-quarter fiscal 2009 results announced by Adolor

Adolor Corporation today reported a net loss of approximately $11.1 million, or ($0.24) per basic and diluted share, for the three months ended September 30, 2009 compared to a net loss of $13.3 million, or ($0.29) per basic and diluted share, for the three months ended September 30, 2008.

29 Oct 2009

Promedior granted European Orphan Medicinal Product Designation for PRM-151

Promedior, Inc., a leader in the development of novel therapeutics for the treatment of fibrotic diseases and tissue remodeling, announced today that the European Commission has granted Orphan Medicinal Product Designation to its lead drug candidate PRM-151 for use in the prevention of scarring post glaucoma filtration surgery.

29 Oct 2009

Interim safety review of LEVADEX completed by MAP Pharmaceuticals

MAP Pharmaceuticals, Inc. today announced that it has completed a planned interim safety review of the open-label, long-term safety extension of the company's Phase 3 FREEDOM 301 clinical trial with its LEVADEX(TM) orally inhaled migraine therapy.

29 Oct 2009

Protox Therapeutics to present Phase 2 study data of PRX302 for benign prostatic hyperplasia

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that detailed data from its open-label Phase 2 clinical study of PRX302 in patients with moderate to severe benign prostatic hyperplasia (BPH) will be presented at the 30th World Congress of the Société Internationale d'Urologie Conference.

29 Oct 2009

Third-quarter 2009 financial results of Antigenics announced

Antigenics Inc. reported today its results for the quarter ended September 30, 2009. The company incurred a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, for the third quarter of 2009, compared with a net loss attributable to common stockholders in the third quarter of 2008 of $11.4 million, or $0.17 per share, basic and diluted.

29 Oct 2009

Ipsen announces sales highlights for the first nine months of 2009

Ipsen reported its sales for the third quarter and first nine months of 2009.

29 Oct 2009

Applied Spine Technologies announces first patient surgery to test safety and effectiveness of Stabilimax system

Applied Spine Technologies (www.appliedspine.com) announces the first patient surgery at Allegheny General Hospital in Pittsburgh, Pennsylvania, as part of their FDA approved Investigational Device Exemption (IDE) clinical trial designed to evaluate the safety and effectiveness of the Stabilimax® Dynamic Spine Stabilization System.

29 Oct 2009

CytRx study reveals potential of molecular chaperones in design of anti-aging pharmaceuticals

CytRx Corporation, a biopharmaceutical company and a leader in molecular chaperone regulation technology, today announced that a paper published in the peer-reviewed journal Gerontology concluded that molecular chaperone amplification may represent a “significant strategy” in the future design of anti-aging pharmaceuticals.

29 Oct 2009

Cempra Pharmaceuticals to present CEM-102 data at the Infectious Diseases Society of America meeting

Cempra Pharmaceuticals today announced data presentations of its lead antibiotic candidate, CEM-102 (fusidic acid), at the Infectious Diseases Society of America, 47th Annual Meeting, Oct. 29 to Nov. 1, 2009, in Philadelphia.

29 Oct 2009

Positive top-line results from Phase IIb clinical trial of cariprazine announced

Forest Laboratories, Inc. and Gedeon Richter Plc today announced positive top-line results from a Phase IIb clinical trial of the novel, investigational antipsychotic agent cariprazine for the treatment of acute exacerbation of schizophrenia.

29 Oct 2009

Cardiome Pharmam, Astellas Pharma begin patient enrolment for ACT 5 trial

Cardiome Pharma Corp. and its co-development partner Astellas Pharma US, Inc. ("Astellas") announced today that patient enrolment has begun for the ACT 5 trial, a confirmatory Phase 3 clinical trial of KYNAPID(TM) (vernakalant hydrochloride) Injection, a drug product candidate under development for the rapid conversion of atrial fibrillation to sinus rhythm.

29 Oct 2009

Supportive data from a preclinical study of SCY-635 to be presented

Drug discovery company SCYNEXIS, Inc. today announced that supportive data from a preclinical study of the Company’s lead product candidate for hepatitis C (HCV), SCY-635, will be presented in a poster session at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) being held in Boston, MA, October 30-November 3, 2009.

29 Oct 2009

Clinical Trial News and Research

OrthoAccel Technologies completes the sale of AcceleDent System in the UK

NIH launches randomized trail to determine whether lower BP goal cuts the risk of heart and kidney diseases

Vitamin D deficiency may account for increased risk of end-stage renal disease in African Americans

USC to develop stem cell-based treatment for age-related macular degeneration with CIRM grant

CIRM awards Cedars-Sinai Heart Institute $5.5 million grant for development of cardiac stem cell therapies

Bolton Medical reports first U.S. trial of its Relay Plus System for endovascular stent-graft procedures

Phase Forward’s InForm GTM electronic data capture solution to be implemented by Bausch & Lomb

World’s first Cesium-131 lung implants performed

Third-quarter fiscal 2009 results announced by Adolor

Promedior granted European Orphan Medicinal Product Designation for PRM-151

Interim safety review of LEVADEX completed by MAP Pharmaceuticals

Protox Therapeutics to present Phase 2 study data of PRX302 for benign prostatic hyperplasia

Third-quarter 2009 financial results of Antigenics announced

Ipsen announces sales highlights for the first nine months of 2009

Applied Spine Technologies announces first patient surgery to test safety and effectiveness of Stabilimax system

CytRx study reveals potential of molecular chaperones in design of anti-aging pharmaceuticals

Cempra Pharmaceuticals to present CEM-102 data at the Infectious Diseases Society of America meeting

Positive top-line results from Phase IIb clinical trial of cariprazine announced

Cardiome Pharmam, Astellas Pharma begin patient enrolment for ACT 5 trial

Supportive data from a preclinical study of SCY-635 to be presented

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News